【摘要】 目的　动态观察肺癌患者血清可溶性细胞间粘附分子 - 1(s ICAM- 1)水平 ,明确 s ICAM- 1在肺癌发展及预后中的意义。方法　选取 2 2例未经任何治疗、组织学类型明确的肺癌 ,在动脉灌注化疗前、化疗后 2周及 8周取血 ,以 EL ISA法测定血清 s ICAM- 1水平。结果　治疗前 ,肺癌组血清 s ICAM- 1水平显著高于正常对照组[(348.4± 10 1.7) mg/ L vs(171.3± 34.2 ) m g/ L ,P <0 .0 1],血清 s ICAM- 1水平与原发灶大小呈正相关 (r=0 .6 0 14,P<0 .0 1) ;血清 s ICAM- 1水平 >30 0 mg/ L组与 <30 0 mg/ L组相比 ,前者的生存率显著低于后者 (2 6 .7%vs 85 .7% ,P<0 .0 5 )。治疗有效组化疗后 2周 s ICAM- 1水平显著低于化疗前 [(2 48.6± 46 .7) mg/ L vs (377.4±48.7) mg/ L ,P <0 .0 1],而治疗无效组 ,化疗前后 s ICAM- 1水平变化不大 (P>0 .0 5 )。结论　肺癌患者血清s ICAM- 1水平与体内肿瘤负荷、临床病期及癌细胞类型有关 ,血清 s ICAM- 1水平可作为疗效评估及预后的指标之一。更多还原

【Abstract】 Objective To evaluate the significance of serum concentrations of soluble intercellular adhesion molecule-1 (sICAM-1) in patients with lung cancer.Methods Serum levels of sICAM-1 in 22 cases were sequentially determined by ELISA.Results Before chemotherapy,the serum levels of sICAM-1 in patients with lung cancer were significantly higher than those in the controls [(348.4±101.7)mg/L vs(171.3±34.2)mg/L,P<0.01] and the serum levels of sICAM-1 were significantly correlated with the size of the primary tumor of the lung (r=0.6014,P<0.01).The survival rate of the group of sICAM-1>300 mg/L was significantly lower than that of the group of sICAM-1<300 mg/L(26.7% vs 85.7%,P<0.05).The serum levels of sICAM-1 of 2 weeks after chemotherapy significantly decreased when the therapy was effective [(248.6±46.7)mg/L vs (377.4±48.7)mg/L,P<0.01],but they kept to the level when the therapy was ineffective [(330.9±130.4)mg/L vs (324.3±128.1)mg/L,(P>0.05].Conclusion The serum levels of sICAM-1 in patients with lung cancer are correlated with the tumor burden and clinical stage as well as the histological type of the cancer.The serum levels of sICAM-1 could be used as one of the measures to evaluate the therapeutic efficacy and to prognosticate the patients.更多还原